首页>投融资
Heartseed
上市
Heartseed is focusing on the development of pluripotent stem cells for the treatment of cardiac failures.In May 2023, Heartseed raised 2 billion JPY at Series D round.In June 2021, Heartseed Inc announced that it has raised 4 Billion-yen in a Series C round funding that brought its total financial backing to 8.2 Billion yen
基本信息
-
公司全称Heartseed Inc
-
类型心脏再生药物开发商
-
产业领域药品研发/制造、生物药
-
公司人数15~50人
-
地址302, The Artcomplex Center of Tokyo 12-9, Daikyo-cho SHINJUKU-KU TOKYO-TO 160-0015; JP;
-
联系电话
-
邮箱contact@heartseed.jp
-
成立时间2015-01-01
投融资
-
2024-07-30上市未透露未透露
-
2023-05-25D轮20亿日元Arcus South East AsiaSMBC Venture CapitalKoei Tecmo CapitalKeio Innovation InitiativeMedical Incubator JapanJapan Co-Invest IV Limited PartnershipNikon-SBI Innovation FundUTokyo IPC
-
2021-06-11C轮3700万美元SMBC CapitalItochu Chemical FrontierMEDIPAL HOLDINGSSumitomo Mitsui Trust InvestmentNissay CapitalKeio Innovation InitiativeMedical Incubator JapanUTokyo IPCSBI Group
-
2020-02-29未透露未透露Itochu Chemical FrontierMEDIPAL HOLDINGS
-
2019-11-22B轮2600万美元Astellas Venture ManagementSMBC Venture CapitalNissay CapitalGene TechnoJMDC JapanSBI Investment
-
2018-07-30A轮8亿日元Shibuya CorporationAstellas Venture ManagementAngel Bridge
-
2016-03-14种子轮1亿日元Angel Bridge
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司，开发工程化单体 IgA 中性粒细胞接合器，以释放中性粒细胞对癌症的肿瘤杀伤能力，以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心（荷兰乌得勒支）进行的开创性工作，并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息